We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HIFS:NASDAQHingham Institution for Savings Analysis

Data as of 2026-04-08 - not real-time

$289.13

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Hingham Institution for Savings is trading near its 20‑day SMA of 276.5 and just below its 50‑day SMA of 292.1, indicating a price that is still within a neutral technical corridor. The RSI of 57.4 suggests modest buying pressure without being overbought, while the MACD histogram is positive (2.86) and the signal line turns bullish, hinting at a potential upside bias. Valuation appears attractive: the trailing P/E of 11.7 is well below the industry average of 16.8, and the price‑to‑book of 1.31 aligns with a fair‑value assessment. Earnings are strong with a trailing EPS of 24.77 and a profit margin above 53%, supported by a revenue growth rate of 55% year‑over‑year. The dividend yield of 0.87% is modest but the payout ratio sits at only 12.7%, indicating ample room for sustainability. A newly authorized share‑repurchase program of up to $20 million provides a potential catalyst for price support. Risk metrics show a beta of 1.04 and a 30‑day volatility of 32.6%, reflecting market‑level sensitivity and relatively high price swings. The stock’s liquidity is solid, with stable volume around 76k shares daily and a market cap of roughly $631 million. Overall, the combination of undervalued metrics, strong earnings, sustainable dividend, and the repurchase plan positions HIFS as a modestly attractive opportunity, though the elevated volatility and sector‑specific headwinds temper enthusiasm.
Given the neutral technical stance, the stock may consolidate near current levels before testing the resistance at 292.8. Investors should monitor the execution of the buy‑back program and any shifts in regional banking credit quality, as these could influence price momentum. In the near term, a cautious “hold” reflects the balance of upside potential and risk, while the medium‑term outlook leans more bullish on the backdrop of solid fundamentals and a compelling valuation gap.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Neutral technical positioning with price near SMA levels
  • Share repurchase program providing price support
  • Sustainable dividend with low payout ratio

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued P/E relative to industry peers
  • Strong earnings growth and high profit margin
  • Low dividend payout indicating earnings durability

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable cash flow and solid ROE
  • Elevated volatility and sector‑specific credit risk
  • Long‑term dividend sustainability and share buy‑back potential

Key Metrics & Analysis

Financial Health

Revenue Growth55.10%
Profit Margin53.08%
P/E Ratio11.7
ROE11.97%
ROA1.21%
P/B Ratio1.3
Op. Cash Flow$35.8M
Industry P/E16.8

Technical Analysis

TrendNeutral
RSI57.4
Support$262.75
Resistance$292.78
MA 20$276.50
MA 50$292.14
MA 200$279.95
MACDBullish
VolumeStable
Fear & Greed Index85.32

Valuation

GradeUndervalued
TypeBlend
Dividend Yield0.87%

Risk Assessment

Beta1.04
Volatility32.59%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.